All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
DUBLIN – Versant Ventures is committing $35 million in series A funding to Bright Peak Therapeutics Inc., which is developing a pipeline of engineered cytokines that are produced using a novel chemical synthesis technique rather than the recombinant methods that have underpinned more than four decades of biotechnology development.